Company news

Jazz Pharmaceuticals plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

May 4, 2020

Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease

April 28, 2020

Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020

April 20, 2020

Jazz Pharmaceuticals Provides COVID-19 Business Update

March 30, 2020

Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

March 24, 2020

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results

February 24, 2020

Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

February 10, 2020

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

January 21, 2020

Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

January 19, 2020

Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

November 14, 2019

Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

November 13, 2019

Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results

November 4, 2019

Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019

October 21, 2019

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

October 9, 2019

Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update

September 17, 2019

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

August 26, 2019

Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

August 11, 2019

Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program

August 5, 2019

Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

July 22, 2019

Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

July 9, 2019

Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

June 24, 2019

Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi(TM) (solriamfetol)

June 16, 2019

Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

April 22, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.